Some days the tape tells you everything in four names.

Some days the tape tells you everything in four names. Today is one of those days.

Let us start with Abbott Laboratories, because that earnings per share number is the one you cannot walk past. Down fifty-three point six percent year over year. The revenue story is fine — up six point six percent, net margin holding near fourteen percent — but that EPS collapse is the whole chapter. What happened is the talc and NEC litigation settlements landed in this period, crushing the bottom line in a way that is accounting real even if it is one-time in nature. The Street will try to normalize it out, and maybe that is fair — but watch whether management uses the noise to quietly reset the bar heading into the back half. That is a move I have seen before. The stock gapped up over ten percent on the print, which tells you expectations were already on the floor. Abbott gets a full teardown. There is too much structure here to leave on the table.

Citizens Financial Group is the one that looks almost too clean. Revenue up sixty-two point seven percent year over year, earnings per share up thirty-one point nine percent, net margin near twenty-five percent — and the stock only moved four point six percent. On a bank. After a number like that. The market is skeptical about whether that revenue surge is durable, or whether there is rate sensitivity and deposit pressure underneath it that does not survive a changed Fed path. I want to see the net interest margin line and the loan book composition before I call it either way.

General Electric is the interesting one because it went the wrong direction. Down four point one percent on the print despite revenue up almost twenty-two percent and earnings per share beating the estimate. At a price-to-earnings of forty-two, the Street was priced for perfection and apparently got slightly less than that. When a name with that multiple sells off on a beat-adjacent quarter, it usually means guidance language was softer than the backward-looking numbers, or the aerospace order book had a sequencing story that spooked somebody in the model. General Electric is on the short list for a full episode.

Intuitive Surgical is almost boring in the best possible way. Revenue up twenty-one point four percent, earnings per share up twenty point nine percent, net margin at twenty-eight percent, stock up three point four percent. The procedure volume numbers and da Vinci system placements are the real metric here — everything else is downstream of that installed base. At nearly forty-eight times earnings, the market is paying for years of recurring instrument and service revenue. The question, as always, is whether hospital capital budgets hold.

Coming up in full teardowns: Abbott Laboratories, because that earnings per share crash deserves a proper accounting, and General Electric, because a selloff on a growth quarter at that multiple has a reason and I want to find it in the filing.

That is the menu. The numbers were always there — most people just do not look. See you at the next filing.